The PLAI-AF Trial, investigating treatment strategies for Atrial Fibrillation, completed its Phase 3 primary data collection on 2025-12-31. This study enrolled 80 participants to compare a hybrid endo-epicardial partial left atrial isolation technique against standard endocardial ablation.
Background
Atrial fibrillation (AF) is a common arrhythmia, and current clinical guidelines recommend ablation for rhythm control in symptomatic patients. While percutaneous ablation shows good results in patients with paroxysmal AF, the optimal technique for those with persistent or long-standing persistent AF remains less clear. Previous research, such as the FAST Trial, compared thoracoscopic epicardial ablation to endocardial catheter ablation, indicating better results for epicardial ablation but with a higher rate of complications. Hybrid epicardial and endocardial ablation strategies have emerged as a potential approach to improve efficacy while managing risks in this challenging patient population.
Trial design
The PLAI-AF Trial is a Phase 3 study designed to evaluate the effectiveness of hybrid endo-epicardial partial left atrial isolation compared to endocardial ablation. The trial enrolled 80 participants diagnosed with Atrial Fibrillation, specifically focusing on patients with Persistent Atrial Fibrillation. The study aims to determine which technique offers superior outcomes for rhythm control in these patients. The interventions being compared are a hybrid endo-epicardial partial left atrial isolation procedure and a standard endocardial ablation procedure.
What this means
The primary completion of the PLAI-AF Trial signifies that all planned data collection from the 80 enrolled participants has concluded as of 2025-12-31. This milestone is a critical step towards understanding the comparative efficacy and safety of hybrid endo-epicardial partial left atrial isolation versus endocardial ablation for persistent atrial fibrillation. The subsequent analysis of this data will be crucial for clinicians and patients, potentially informing future treatment guidelines and offering a clearer path for managing persistent AF, where current ablation techniques still present challenges in achieving durable rhythm control.
Source
Information regarding the primary completion of this trial was obtained from ClinicalTrials.gov, a public database of clinical studies. The event, identified as primary completion for study NCT05723536, was recorded on 2025-12-31 on clinicaltrials.gov.